Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Miguel Martín, Yolanda Jeréz Gilarranz et al.|Breast Cancer Research and Treatment|2024Cited by 21